Novo Nordisk reported 76.86B in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Bausch Health Companies USD 2.53B 270M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
GlaxoSmithKline GBP 7.99B 470M Jun/2025
Merck USD 15.81B 280M Jun/2025
Novartis USD 14.05B 821M Jun/2025
Novo Nordisk 76.86B 1.23B Jun/2025
Novo Nordisk DKK 154.94B 76.85B Jun/2025
Pacira USD 181.1M 12.18M Jun/2025
Sanofi EUR 9.99B 90M Jun/2025
Supernus Pharmaceuticals USD 165.5M 15.7M Jun/2025